Cited by 420Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Reversible memory loss in a mouse transgenic model of Alzheimer’s disease

Open access

Kotilinek, Linda A., Bacskai, Brian, Westerman, Marcus, Kawarabayashi, Takeshi, Younkin, Linda, Hyman, Bradley T., Younkin, Steven, Ashe, Karen H.·2002·The Journal of Neuroscience

DOI 10.1523/jneurosci.22-15-06331.2002PMC PMC6758140

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition, believed to be irreversible, characterized by inexorable deterioration of memory and intellect, with neuronal loss accompanying amyloid plaques and neurofibrillary tangles. In an amyloid precursor protein transgenic mouse model, Tg2576, little or no neuronal loss accompanies age-related memory impairment or the accumulation of Abeta, a 40-42 aa polypeptide found in plaques. Recently, we have shown inverse correlations between brain Abeta and memory in Tg2576 mice stratified by age (Westerman et al., 2002). Broadening the age range examined obscured this relationship, leading us to propose that small, soluble assemblies of Abeta disrupt cognitive function in these mice. Here we show that memory loss can be fully reversed in Tg2576 mice using intraperitoneally administered BAM-10, a monoclonal antibody recognizing the N terminus of Abeta. The beneficial effect of BAM-10 was not associated with a significant Abeta reduction, but instead eliminated the inverse relationship between brain Abeta and memory. We postulate that BAM-10 acts by neutralizing Abeta assemblies in the brain that impair cognitive function. Our results indicate that a substantial portion of memory loss in Tg2576 mice is not permanent. If these Abeta assemblies contribute significantly to memory loss in AD, then successfully targeting them might improve memory in some AD patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.22-15-06331.2002

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Self-citation
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 10×
“A was measured by ELISA using the 3160 capture antibody described previously (Kawarabayashi et al., 2001).”
BackgroundMethodInfluentialSelf-citation
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858

Flagged first, then by citations

Show all 13 references

Sorted by citations

Items 101–200 of 418

Chronic Psychosocial Stress Exacerbates Impairment of Cognition and Long-Term Potentiation in β-Amyloid Rat Model of Alzheimer's Disease
Srivareerat, M., Tran, T. T., Alzoubi, K. H., & Alkadhi, K. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.021 · Cited by 128
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A antibody
Bales, K. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27120 · Cited by 123
Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations
Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700373200 · Cited by 118
Impact of amyloid imaging on drug development in Alzheimer's disease
Mathis, C. A., Lopresti, B. J., & Klunk, W. E. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.015 · Cited by 121
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117
The various aggregation states of β-amyloid 1–42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression
Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O., & Tabaton, M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.01.021 · Cited by 119
Phagocytic Clearance in Neurodegeneration
Sokolowski, J. D., & Mandell, J. W. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.051 · Cited by 120
Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters
Алексеевна, Г. М., Davidova, T. B., Mališauskas, M., Sewell, R. D. E., Voskresenskaya, N. I., Wilhelm, K., Elistratova, E. I., Sherstnev, V. V., & Morozova‐Roche, L. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.03.023 · Cited by 112
Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration
Eriksen, J. L., & Janus, C. G. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9118-z · Cited by 146
Small molecule blockers of the Alzheimer Aβ calcium channel potently protect neurons from Aβ cytotoxicity
Díaz, J. C., Šimáková, O., Jacobson, K. A., Arispe, N. J., & Pollard, H. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813355106 · Cited by 116
ACAT1/SOAT1 as a Therapeutic Target for Alzheimer's Disease
Shibuya, Y., Chang, C. C., & Chang, T.-Y. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.161 · Cited by 113
Single Chain Variable Fragments against β-Amyloid (Aβ) Can Inhibit Aβ Aggregation and Prevent Aβ-Induced Neurotoxicity
Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y. L., Goud, G. N., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi049933o · Cited by 113
BACE1 gene deletion: Impact on behavioral function in a model of Alzheimer’s disease
Kobayashi, D., Zeller, M., Cole, T., Buttini, M., McConlogue, L., Sinha, S., Freedman, S., Morris, R. G. M., & Chen, K. S. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.01.002 · Cited by 111
ADDLs and the signaling web that leads to Alzheimer’s disease
Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 113
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease
Klein, W. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.11.003 · Cited by 109
Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease
PEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses
Chackerian, B., Rangel, M., Hunter, Z. N., & Peabody, D. S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.059 · Cited by 110
Natural human antibodies to amyloid beta peptide
Szabo, P., Relkin, N. R., & Weksler, M. E. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.03.007 · Cited by 109
Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials
Wilcock, D. M., & Colton, C. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15404 · Cited by 107
A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ
Head, E., Pop, V., Vasilevko, V., Hill, M., Saing, T., Sarsoza, F. M., Nistor, M., Christie, L., Milton, S. C. F., Glabe, C. G., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0208-08.2008 · Cited by 107
Combined treatment with the phenolics (−)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice
Mori, T., Koyama, N., Tan, J., Segawa, T., Maeda, M., & Town, T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004280 · Cited by 103
An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies
Ryan, D. A., Narrow, W. C., Federoff, H. J., & Bowers, W. J. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.05.001 · Cited by 102
Which Memory Task for My Mouse? A Systematic Review of Spatial Memory Performance in the Tg2576 Alzheimer's Mouse Model
Stewart, S., Cacucci, F., & Lever, C. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101827 · Cited by 106
Why Alzheimer's is a disease of memory: The attack on synapses by Aß oligomers (ADDLs)
Viola, K. L., Velasco, P. T., & Klein, W. L. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02982587 · Cited by 97
Anti-oligomeric Aβ Single-chain Variable Domain Antibody Blocks Aβ-induced Toxicity Against Human Neuroblastoma Cells
Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.068 · Cited by 96
Mice as models: Transgenic approaches and Alzheimer's disease
Games, D., Buttini, M., Kobayashi, D. T., Schenk, D., & Seubert, P. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s316 · Cited by 93
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages
Asuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wısnıewskı, T., & Sigurdsson, E. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05149.x · Cited by 91
Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease
Velázquez, R., Tran, A., Ishimwe, E., Denner, L. A., Dave, N., Oddo, S., & Dineley, K. T. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.003 · Cited by 89
Bapineuzumab
Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 92
Prions, prionoids and pathogenic proteins in Alzheimer disease
Ashe, K. H., & Aguzzi, A. (2013) · Prion · doi:10.4161/pri.23061 · Cited by 89
Self-citation
Mitochondrial quality control and neurological disease: an emerging connection
de Castro, I. P., Martins, L. M., & Tufi, R. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001456 · Cited by 92
Pathogenesis of Abeta Oligomers in Synaptic Failure
Sivanesan, S., Tan, A., & Rajadas, J. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030011 · Cited by 85
Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons
Kelly, B. L., & Ferreira, A. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.03.047 · Cited by 85
Developing novel immunogens for a safe and effective Alzheimer's disease vaccine
Lemere, C. A. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17506-4 · Cited by 83
Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice
Chauhan, N. B., & Sandoval, J. (2007) · Phytotherapy Research · doi:10.1002/ptr.2122 · Cited by 86
Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies
Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 83
Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition
Denver, P., & McClean, P. L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238608 · Cited by 89
Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapies
Rowan, M. J., Klyubin, I. V., Wang, Q., & Anwyl, R. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330563 · Cited by 83
Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice
Hyde, L. A., Kazdoba, T. M., Grilli, M., Lozza, G., Brussa, R., Zhang, Q., Wong, G. T., McCool, M. F., Zhang, L., Parker, E. M., et al. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.12.017 · Cited by 83
Gene Vaccination to Bias the Immune Response to Amyloid-β Peptide as Therapy for Alzheimer Disease
Qu, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1859 · Cited by 80
APP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79
Drugs targeting alzheimer’s disease: Some things old and some things new
Michaelis, M. L. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035840 · Cited by 78
Gallic acid is a dual α/β-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice
Mori, T., Koyama, N., Yokoo, T., Segawa, T., Maeda, M., Sawmiller, D. R., Tan, J., & Town, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012330 · Cited by 82
Genetic Modulation of Soluble A Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease
Fowler, S., Chiang, A. C. A., Savjani, R. R., Larson, M., Sherman, M. A., Schuler, D. R., Cirrito, J. R., Lesné, S., & Jankowsky, J. L. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0572-14.2014 · Cited by 80
Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research
Jack, C. R., Marjańska, M., Wengenack, T. M., Reyes, D. A., Curran, G. L., Lin, J., Preboske, G. M., Poduslo, J. F., & Garwood, M. (2007) · The Neuroscientist · doi:10.1177/1073858406295610 · Cited by 76
Anti-dementia drugs and hippocampal-dependent memory in rodents
Yuede, C. M., Dong, H., & Csernansky, J. G. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282da278d · Cited by 76
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease
Spires‐Jones, T. L., Mielke, M. L., Rozkalne, A., Meyer‐Luehmann, M., de Calignon, A., Bacskai, B. J., Schenk, D., & Hyman, B. T. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.011 · Cited by 78
Self-citation
Protofibrils of amyloid β-protein inhibit specific K+ currents in neocortical cultures
Ye, C. P., Selkoe, D. J., & Hartley, D. M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00068-8 · Cited by 74
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
Bouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 74
A Review of the Current Mammalian Models of Alzheimer’s Disease and Challenges That Need to Be Overcome
Mckean, N. E., Handley, R. R., & Snell, R. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313168 · Cited by 81
Carvedilol as a potential novel agent for the treatment of Alzheimer's disease
Wang, J., Ono, K., Dickstein, D. L., Arrieta‐Cruz, I., Zhao, W., Qian, X., Lamparello, A. J., Subnani, R., Ferruzzi, M. G., Pavlides, C., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.004 · Cited by 76
Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein
Liskowsky, W., & Schliebs, R. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.010 · Cited by 73
Immunotherapy for Alzheimer’s disease: past, present and future
Spencer, B. J., & Masliah, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00114 · Cited by 73
Nanometric agents in the service of neuroscience: Manipulation of neuronal growth and activity using nanoparticles
Polak, P., & Shefi, O. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.03.005 · Cited by 70
Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans
Lemere, C. A., Maier, M., Jiang, L., Peng, Y., & Seabrook, T. J. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.77 · Cited by 68
Lifelong immunization with human β-amyloid (1–42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging
Jensen, M. T., Mottin, M. D., Cracchiolo, J. R., Leighty, R. E., & Arendash, G. W. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.09.055 · Cited by 69
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels
Lawlor, P. A., Bland, R. J., Das, P., Price, R. W., Holloway, V., Smithson, L., Dicker, B. L., During, M. J., Young, D., & Golde, T. E. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-11 · Cited by 67
Impaired Visuospatial Recognition Memory but Normal Object Novelty Detection and Relative Familiarity Judgments in Adult Mice Expressing the APPswe Alzheimer's Disease Mutation.
Hale, G., & Good, M. A. (2005) · Behavioral Neuroscience · doi:10.1037/0735-7044.119.4.884 · Cited by 71
Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice
Qu, B., Boyer, P. J., Johnston, S. A., Hynan, L. S., & Rosenberg, R. N. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.02.006 · Cited by 67
What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders
Westmark, C. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.122 · Cited by 63
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression
Colasanti, T., Barbati, C., Rosano, G. M. C., Malorni, W., & Ortona, E. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.008 · Cited by 61
Nanoscience enables ultrasensitive detection of Alzheimer's biomarker
Keating, C. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500024102 · Cited by 61
The immune system, amyloid‐β peptide, and Alzheimer's disease
Weksler, M. E., Gouras, G. K., Relkin, N. R., & Szabo, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00264.x · Cited by 60
Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
Lichtlen, P., & Mohajeri, M. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05064.x · Cited by 60
A case for a non‐transgenic animal model of Alzheimer's disease
Stéphan, A., & Phillips, A. G. (2005) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00113.x · Cited by 63
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies
Lindhagen‐Persson, M., Brännström, K., Vestling, M., Steinitz, M. O., & Olofsson, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013928 · Cited by 57
Antibody-Mediated Clearance of Amyloid-β Peptide from Cerebral Amyloid Angiopathy Revealed by QuantitativeIn VivoImaging
Prada, C. M., Garcı́a-Alloza, M., Betensky, R. A., Zhang-Nunes, S., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5426-06.2007 · Cited by 56
Self-citation
Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease
Mori, T., Koyama, N., Tan, J., Segawa, T., Maeda, M., & Town, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762658 · Cited by 57
Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice
Zhuo, J., Prescott, S., Murray, M. E., Zhang, H.-Y., Baxter, M. G., & Nicolle, M. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.034 · Cited by 57
Immunotherapy Targeting α-Synuclein, with Relevance for Future Treatment of Parkinson‘s Disease and Other Lewy Body Disorders
Lindström, V., Ihse, E., Fagerqvist, T., Bergström, J. J. E., Nordström, E. K. L., Möller, C., Lannfelt, L., & Ingelsson, M. (2014) · Immunotherapy · doi:10.2217/imt.13.162 · Cited by 56
Deleterious effects of soluble amyloid-β oligomers on multiple steps of synaptic vesicle trafficking
Park, J., Jang, M., & Chang, S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.03.004 · Cited by 57
Repair of amyloid β(25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to
Tohda, C., Tamura, T., & Komatsu, K. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03449-8 · Cited by 56
Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice
Mably, A. J., Liu, W., Donald, J. M. M., Dodart, J., Bard, F., Lemere, C. A., O’Nuallain, B., & Walsh, D. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.008 · Cited by 55
Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 55
Learning and Memory Deficits in APP Transgenic Mouse Models of Amyloid Deposition
Morgan, D. (2003) · Neurochemical Research · doi:10.1023/a:1023255106106 · Cited by 52
Neuropathology of Alzheimer's Disease
Gómez‐Isla, T., Spires‐Jones, T. L., de Calignon, A., & Hyman, B. T. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01222-5 · Cited by 55
Self-citation
β-Secretase, APP and Aβ in Alzheimer’s Disease
Vassar, R. J. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_4 · Cited by 52
Non-Steroidal Anti-Inflammatory Drugs and Cognitive Function: Are Prostaglandins at the Heart of Cognitive Impairment in Dementia and Delirium ?
Cunningham, C. M., & Skelly, D. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9312-5 · Cited by 51
Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 52
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 51
Physical exercise protocols in animal models of Alzheimer’s disease: a systematic review
Sousa, R. A. L. D., Rodrigues, C. M., Mendes, B. F., Caria, A. C. I., Dias‐Peixoto, M. F., & Cassilhas, R. C. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00633-z · Cited by 54
Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease
Lovasic, L., Bauschke, H. H., & Janus, C. (2004) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00104.x · Cited by 53
Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576
Chauhan, N. B., Siegel, G. J., & Feinstein, D. L. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.09.014 · Cited by 50
Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice
Mori, T., Koyama, N., Segawa, T., Maeda, M., Maruyama, N., Kinoshita, N., Hou, H., Tan, J., & Town, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568212 · Cited by 51
Epitope‐based DNA vaccine for Alzheimer's disease: Translational study in macaques
Evans, C. F., Davtyan, H., Petrushina, I., Hovakimyan, A., Davtyan, A., Hannaman, D., Cribbs, D. H., Agadjanyan, M. G., & Ghochikyan, A. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.505 · Cited by 47
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Le, N. P. L., Bowden, T. A., Struwe, W. B., & Crispin, M. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.04.016 · Cited by 48
Searching for new animal models of Alzheimer′s disease
Epis, R., Gardoni, F., Marcello, E. E., Genazzani, A. A., Canonico, P. L., & Luca, M. D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.020 · Cited by 51
Immunotherapy against APP β-Secretase Cleavage Site Improves Cognitive Function and Reduces Neuroinflammation in Tg2576 Mice without a Significant Effect on Brain Aβ Levels
Rakover, I. S., Arbel, M., & Solomon, B. (2007) · Neurodegenerative Diseases · doi:10.1159/000103250 · Cited by 45
Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice
MORGAN, D. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.017 · Cited by 46
Active β-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of β-Amyloid
Chen, G., Chen, K. S., Kobayashi, D. T., Barbour, R., Motter, R. N., Games, D., Martin, S. J., & Morris, R. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3710-06.2007 · Cited by 47
A limited role for microglia in antibody mediated plaque clearance in APP mice
Garcı́a-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 47
Self-citation
Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid-β and Interleukin-4
Frazer, M. E., Hughes, J. E., Mastrangelo, M. A., Tibbens, J. L., Federoff, H. J., & Bowers, W. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.39 · Cited by 47
Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer’s transgenic mouse lines differing in Aβ deposition
Leighty, R. E., Nilsson, L. N. G., Potter, H., Costa, D. A., Low, M. A., Bales, K. R., Paul, S. M., & Arendash, G. W. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.11.004 · Cited by 47
Mouse models of Alzheimer's disease: The long and filamentous road
Phinney, A. L., Horne, P., Yang, J., Janus, C., Bergeron, C., & Westaway, D. A. (2003) · Neurological Research · doi:10.1179/016164103101202020 · Cited by 47

Authors: Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H.
Affiliations: University of Minnesota (US)
Harvard University (US)
Mayo Clinic (US)
Mayo Clinic in Florida (US)
ORCID: Bacskai, Brian
Kawarabayashi, Takeshi
Hyman, Bradley T.
Ashe, Karen H.
Venue: The Journal of Neuroscience
Publisher: Society for Neuroscience
Published: 2002-08-01
Volume: 22
Issue: 15
Pages: 6331-6335
ISSN: 0270-6474 (ISSN-L)
1529-2401
DOI: 10.1523/jneurosci.22-15-06331.2002
PMC: PMC6758140
OpenAlex: W1705725530
Cited by: 420
References: 13
Citations by year: 2026: 1 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 12 · 2016: 7 · 2015: 10 · 2014: 15 · 2013: 28 · 2012: 14
FWCI: 18.41
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neuroscience (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
National Institutes of Health
National Institute on Aging (P01AG015453)
National Institute of Mental Health (R01MH065465)
National Institute of Neurological Disorders and Stroke (R01NS033249)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, memory loss, amyloid-beta, monoclonal antibodies, Tg2576 mice, amyloid precursor protein, cognitive function, age-related memory impairment
MeSH terms: Aging, Alzheimer Disease, Animals, Antibodies, Monoclonal, Behavior, Animal, Brain Chemistry, Cognition, Disease Models, Animal, Female, Immunization, Passive, Injections, Intraperitoneal, Male, Memory, Memory Disorders, Mice, Transgenic, Remission Induction, Spatial Behavior, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reversible memory loss in a mouse transgenic model of Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks